Merck KGaA (CHIX:MRKD) Beta: 1.1169 (As of Jun. 24, 2026)


CHIX:MRKD Merck KGaA CHIX:MRKD
83 GF Score
Price €128.75
GF Value €140.71
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Merck KGaA Beta?

Merck KGaA CHIX:MRKD 83 Beta is 1.1169 as of Jun. 24, 2026. GuruFocus rates CHIX:MRKD with a GF Score™ of 83/100 and a GF Value™ of €140.71 (Fairly Valued). The stock has 9 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Merck KGaA's Beta is 1.1169.


Merck KGaA  (CHIX:MRKd) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Merck KGaA Beta Related Terms


Merck KGaA Beta Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Beta Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.00 0.83 0.65

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.74 0.54 0.65 0.86

CHIX:MRKD vs ZTS, UTHR, VTRS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck KGaA Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Beta distribution charts can be found below:

* The bar in red indicates where Merck KGaA's Beta falls into.


CHIX:MRKD
83GF Score
Merck KGaA CHIX:MRKD
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.1169 mean?
Merck KGaA (CHIX:MRKD) has a Beta of 1.1169 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Merck KGaA and its competitors.
Is Merck KGaA's Beta too high?
Merck KGaA's current Beta is 1.1169. Overall, Merck KGaA has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Beta compare to ZTS and UTHR?
Merck KGaA's Beta of 1.1169 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Merck KGaA and its competitors. Merck KGaA's current Beta is 1.1169. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (CHIX:MRKD) is currently considered Fairly Valued. The stock's GF Value™ is €140.71, compared to a current price of €128.75 — trading 8.5% below its estimated fair value. The current Beta is 1.1169. Merck KGaA's overall GF Score™ is 83/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Merck KGaA (CHIX:MRKD), the current Beta is 1.1169 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (CHIX:MRKD) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of €128.75 is trading 8.5% below its estimated GF Value™ of €140.71. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for CHIX:MRKD:

  • Beta: 1.1169
  • GF Value™: €140.71 vs. price of €128.75 (8.5% below fair value)
  • GF Score™: 83/100 with 9 warning signs

No single metric tells the full story. See the CHIX:MRKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
83GF Score

Get the complete analysis for CHIX:MRKD

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€128.75
Price
€140.71
GF Value